Clinical Trial Update: Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating an initial vancomycin taper to prevent recurrent Clostridioides difficile infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Vancomycin (vancomycin)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Clostridium Difficile Infection | Phase 3 | Status: COMPLETED